http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101432172-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B42D1-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A63H33-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B42D3-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B42D15-0086 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate | 2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2014-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2014-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101432172-B1 |
titleOfInvention | Composition for diagnosis of radio-resistance or radio-sensitive MRFAP1 marker and use thereof |
abstract | The present invention relates to a radiation-sensitive or sensitive diagnostic composition comprising an agent for screening a marker for radiation resistance or sensitivity of a cancer and measuring the presence of the marker, a radiation-sensitive or sensitive diagnostic kit comprising the composition, Or susceptibility to radiation or radiation therapy in cancer patients. By using the radiation-sensitive or sensitive diagnostic composition of the present invention, it is possible to provide radiation therapy that is customized by judging the radiation resistance or sensitivity of cancer cells to be treated with radiation, and to improve the therapeutic effect and side effects Can be reduced. It can also be used to judge the prognosis of patients treated with radiotherapy (to predict the therapeutic effect). |
priorityDate | 2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 465.